Gilsenan A, Midkiff K, Harris D, Kellier-Steele N, McSorley D, Andrews EB. Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study. J Bone Miner Res. 2020 Feb;36(2):244-51. doi: 10.1002/jbmr.4188
Midkiff K, Harris D, Gilsenan A, Kellier-Steele N, McSorley D, Andrews EB. Results of a long-term postmarketing case series of adult osteosarcoma and teriparatide in the United States. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):688. doi: 10.1002/pds.4864
Gilsenan A, Midkiff K, Harris D, Kellier-Steele N, Andrews E. Results from a fifteen-year postmarketing drug safety study of adult osteosarcoma and teriparatide in the US. Poster presented at the 2019 NAACCR / IACR Combined Annual Conference; June 11, 2019. Vancouver, Canada.
Midkiff K, Andrews EB, Gilsenan A, Harris D. Comparing strategies to monitor for a potential association between teriparatide and adult osteosarcoma. Poster presented at the 10th Asian Conference on Pharmacoepidemiology (ACPE); October 31, 2017. Brisbane, Australia.
Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, Masica D. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012 Dec;27(12):2429-37. doi: 10.1002/jbmr.1768
Naslund MJ, Gilsenan AW, Midkiff KD, Bown A, Wolford ET, Wang A. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting. Int J Clin Pract. 2007 Sep 1;61(9):1437-45.
Naslund M, Gilsenan AW, Midkiff KD, Wolford E, Bown A, Wang J. The prevalence of luts and prostate enlargement in the primary care setting. Poster presented at the Annual Meeting of the American Urological Association; 2007.